Argenx And Zai Lab Announce China's National Medical Products Administration Approved The Supplemental SBLA For VYVGART Hytrulo In Chronic Inflammatory Demyelinating Polyneuropathy
Argenx And Zai Lab Announce China's National Medical Products Administration Approved The Supplemental SBLA For VYVGART Hytrulo In Chronic Inflammatory Demyelinating Polyneuropathy
Argenx和再鼎醫藥宣佈，中國國家藥品監督管理局已批准VYVGARt Hytrulo用於慢性炎症性脫髓鞘周圍神經病的補充SBLA。
Argenx And Zai Lab Announce China's National Medical Products Administration Approved The Supplemental SBLA For VYVGART Hytrulo In Chronic Inflammatory Demyelinating Polyneuropathy
Argenx和再鼎醫藥宣佈，中國國家藥品監督管理局已批准VYVGARt Hytrulo用於慢性炎症性脫髓鞘周圍神經病的補充SBLA。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間